Fig. 1From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical triala PFS according to treatment arm. b PFS according to tumor location. c PFS according to radiation-induced or de novo sarcomaBack to article page